Navigation Links
Ondine's CEO Carolyn Cross to be a Plenary Session Speaker at 14th World Congress of International Photodynamic Association
Date:5/14/2013

Vancouver, British Columbia (PRWEB) May 14, 2013

Ondine Biomedical Inc. announces that its CEO, Carolyn Cross, will be a Plenary Session Speaker at the World Congress of the of the International Photodynamic Association (IPA) on May 28th through May 31st, 2013. Carolyn Cross will be representing the field of work in Photodisinfection (also known as antimicrobial Photodynamic Therapy or aPDT). Ondine Biomedical is the global leader in the design and development of Photodisinfection based therapies, and is involved with all aspects of technology, product and clinical development through to commercialization of photodisinfection products. Photodisinfection based applications under development at Ondine include products for the dental, hospital acquired infection prevention (VAP, SSI, UTI, Blood Catheter, GI) and chronic sinusitis markets. Ms. Cross stated her speech will provide an “excellent opportunity to talk about the advances Ondine has made in Photodisinfection in a variety of applications and the larger implications those advances represent for Photodynamic technology.”

The IPA World Congress is a biannual conference highlighting the advances in scientific and clinical research around the world. This year's Congress is being held May 28th to May 31st, 2013 at the Ritz-Carlton Hotel, Seoul, Korea. All of the leaders in the field of PDT and their work will be represented during this event. Clinicians, scientists, researchers, hospital administrators, students are welcome to participate at this year's conference. Registration details are available here: IPA Registration

About the International Photodynamic Association

The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching photodynamic therapy (PDT) and photodiagnosis (PD). The purpose of the IPA is to promote the study of diagnosis and treatment using light and photosensitisers, to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organises an International Congress every two years to highlight leading research activities in the clinical and basic research aspects of PDT

About Carolyn Cross:

Carolyn Cross is the founder and CEO of Ondine Biomedical Inc., formed in 1999, and has over 18 years of direct experience working with early stage companies and has 25 years of experience with public market securities. Previously, Carolyn was responsible for managing pension, pooled, mutual and private client funds as a Vice President with Royal Bank Investment Management Inc., the fund management arm of the Royal Bank of Canada. Carolyn is currently a member of the Women’s Presidents Organization, the International Women’s Forum, the Toronto Society of Financial Analysts, the Courthill and Cherie Blair Foundations, and the Association for Professionals in Infection Control and Epidemiology. Carolyn Cross is the Founder of OrGenX Biopharma Corporation, a WEConnect certified company.

Read the full story at http://www.prweb.com/releases/papdt/WorldCongress/prweb10728611.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
2. NASA develops super-black material that absorbs light across multiple wavelength bands
3. Micross Components Hosts Stop on "Drive for Innovation" Tour
4. BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector
5. Autism mutations, scattered across many genes, merge into common network of interactions
6. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
7. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
8. Albany CrossFit Wins Competition By Raising $32,579 For St. Jude Children's Research Hospital
9. Its Indiana State Fair Season: New BioCrossroads Report Emphasizes Opportunities in Food and Agriculture Innovation
10. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
11. CureLauncher is a New Website That Connects Patients to Trials Across the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):